S. Chandarlapaty

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

This paper develops a multimodal transformer model using H&E images and text reports to predict recurrence scores in hormone receptor-positive breast cancer, achieving high accuracy and generalizability.

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

ERα-LBD, a novel isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance

The paper identifies ER-LBD, a novel estrogen receptor alpha isoform, which promotes breast cancer growth and resistance to endocrine therapy.

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

The paper analyzes genomic data from 25,000 patients to identify associations between genomic alterations and metastatic patterns across 50 tumor types, finding chromosomal instability correlates with metastatic burden in some cancers.

Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns

The paper identifies actionable genomic vulnerabilities in cancer by analyzing driver alteration co-occurrence patterns and validates predictions in mice, improving drug response modeling from patient data.

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.